article Open AccessTop 1% cited
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Ophthalmology · 2012 · Vol. 119(7) · pp. 1388–1398
Daniel Martín(Cleveland Eye Clinic)Maureen G. Maguire✉(University of Pennsylvania)Stuart L. Fine(University of Colorado Denver)Gui‐Shuang Ying(University of Pennsylvania)Glenn J. Jaffe(Duke University)Juan E. Grunwald(University of Pennsylvania)Cynthia A. Toth(Duke University)Maryann Redford(National Eye Institute)Frederick L. Ferris(National Institutes of Health)
Retinal Diseases and TreatmentsOcular Diseases and Behçet’s SyndromeRetinal Imaging and AnalysisMedicineRanibizumabBevacizumabMacular degenerationRegimenVisual acuityRandomized controlled trialConfidence intervalDosingOphthalmology
MeSH terms
BevacizumabRanibizumabAgedAged, 80 and overFemaleFluorescein AngiographyFollow-Up StudiesHumansMaleMiddle AgedVisual AcuityTreatment OutcomeAngiogenesis InhibitorsTomography, Optical CoherenceVascular Endothelial Growth Factor A
Citations
1,702
FWCI
160.14
field-weighted impact
References
22
Percentile
100%
vs. same field & year
Citations per year
Cited by
Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration
Ophthalmology · 2016 · 690 citations
Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON
Ophthalmology · 2013 · 999 citations
Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)
British Journal of Ophthalmology · 2014 · 633 citations
Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration
Ophthalmology · 2013 · 801 citations
Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
British Journal of Ophthalmology · 2014 · 602 citations
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
Ophthalmology · 2016 · 1,008 citations
Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
Ophthalmology · 2012 · 2,431 citations
Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
British Journal of Ophthalmology · 2014 · 367 citations
References
Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2
American Journal of Ophthalmology · 2001 · 813 citations
Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With Verteporfin
Archives of Ophthalmology · 1999 · 2,186 citations
Longitudinal Data Analysis for Discrete and Continuous Outcomes
Biometrics · 1986 · 7,806 citations
Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2
American Journal of Ophthalmology · 2002 · 669 citations
The central role of the propensity score in observational studies for causal effects
Biometrika · 1983 · 30,427 citations
Regression Models and Life-Tables
Journal of the Royal Statistical Society Series B (Statistical Methodology) · 1972 · 38,926 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.